SGN-35T for Lymphoma

Recruiting at 11 trial locations

Overseen By Seagen Trial Information Support

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Seagen Inc.

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

110 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug in adults with certain types of lymphoma that haven't responded to other treatments. The drug works by targeting a protein on cancer cells and delivering a substance that kills them. This drug has shown high selectivity against specific cancer cells and has been approved for treating lymphoma patients.

Research Team

Medical Monitor

Principal Investigator

Seagen Inc.

Eligibility Criteria

This trial is for adults with advanced lymphomas, such as Hodgkin's and various T-cell lymphomas, who have tried other treatments without success or for whom no standard treatment is appropriate. Participants must have a certain level of CD30 expression in their tumors (except for specific types where it's always present) and be physically able to undergo the treatment, with an ECOG score ≤1.

Inclusion Criteria

My cancer's CD30 status does not affect my eligibility.

To be eligible for the study, those who have not had ASCT must either decline the treatment or they are ineligible.

My condition is specified in the trial's disease focus.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part A

Participants receive SGN-35T to determine the best dose and dosing schedule

Approximately 12 weeks

Treatment Part B

Continuation of dose determination and schedule optimization for SGN-35T

Approximately 12 weeks

Treatment Part C

Participants receive the determined dose to evaluate safety and efficacy

Approximately 12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

30-37 days after last study treatment

Treatment Details

Interventions

• SGN-35T

Trial Overview SGN-35T, a new drug delivered through vein infusion, is being tested for safety and effectiveness in treating different types of lymphoma. The trial has three parts: determining the best dose and schedule (Parts A & B), then assessing its safety at that dose while checking if it works against select lymphomas (Part C).

Participant Groups

Group I: SGN-35T Experimental Treatment 1 Intervention

SGN-35T monotherapy

Who Is Running the Clinical Trial?

Seagen Inc.

Lead Sponsor

Trials

212

Recruited

73,800+

Founded

1997

Headquarters

Bothell, USA

Known For

Antibody-Drug Conjugates

Top Products

Adcetris (brentuximab vedotin), Tukysa (tucatinib), Padcev (enfortumab vedotin-ejfv), Tivdak (tisotumab vedotin-tftv)

Dr. Roger Dansey

Seagen Inc.

Chief Medical Officer since 2018

MD from University of Witwatersrand

David R. Epstein

Seagen Inc.

Chief Executive Officer since 2022

BSc in Pharmacy from Rutgers University, MBA from Columbia University

Seagen, a wholly owned subsidiary of Pfizer

Lead Sponsor

Trials

20

Recruited

4,900+